Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece.
Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece.
Leuk Res. 2014 Feb;38(2):161-5. doi: 10.1016/j.leukres.2013.10.015. Epub 2013 Oct 28.
Data derived from clinical trials consistently show a prolongation of overall survival of late-stage MDS patients with the introduction of azacytidine. Nevertheless, the applicability of the above results to real-world clinical settings may be questionable due to the strict design, the controlled medical environment, and the limited patient sample of explanatory studies. We retrospectively compared the outcome of two well-balanced groups of late-stage MDS patients. The first consisted of 46 patients treated with azacytidine (AZA cohort) and the second of 41 patients treated with other agents (non-AZA cohort). Patients in the AZA cohort displayed superior survival compared to the non-AZA ones. However, subgroup analysis revealed that azacytidine conferred a significant survival advantage only in patients with AML-MDS and those who attained a CR at any time after treatment initiation, while all other patients displayed comparable outcome with the non-AZA cohort. Larger series are needed to determine which patients benefit most from azacytidine therapy.
临床试验得出的数据一致表明，阿扎胞苷的引入可延长晚期 MDS 患者的总生存期。然而，由于解释性研究的严格设计、受控的医疗环境和有限的患者样本，上述结果在真实临床环境中的适用性可能值得怀疑。我们回顾性地比较了两组晚期 MDS 患者的结果。第一组包括 46 例接受阿扎胞苷治疗的患者（AZA 组），第二组包括 41 例接受其他药物治疗的患者（非 AZA 组）。AZA 组患者的生存情况优于非 AZA 组。然而，亚组分析显示，阿扎胞苷仅在 AML-MDS 患者和任何时间达到 CR 的患者中具有显著的生存优势，而所有其他患者的结果与非 AZA 组相似。需要更大的系列来确定哪些患者最受益于阿扎胞苷治疗。
